Angde Biotech Pharmaceutical Co., Ltd.: Clinical Trials

5 trials sponsored by Angde Biotech Pharmaceutical Co., Ltd., newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 unknown, 1 completed. 3 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 23Unknown 3
Phase 31Completed 1

Follow Angde Biotech Pharmaceutical Co., Ltd.: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of PEG-EPO Injection (CHO Cells) for Maintenance Therapy of Patients With Renal Anemia .
Recombinant human erythropoietin injection, Human erythropoietin injection - Renal Anemia
Phase 2UnknownAngde Biotech Pharmaceutical Co., Ltd.1502022-04-132022-11-29
A Study of r-PA Treating Patients With Acute Ischemic Stroke(RAISE)
Injection of recombinant human tissue plasminogen kinase derivatives, Recombinant human tissue plasminogen activator - Acute Ischemic Stroke
Phase 3CompletedAngde Biotech Pharmaceutical Co., Ltd.14122022-03-212024-03-04
Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA)
Recombinant human tissue-type plasminogen activator derivative, Recombinant human tissue-type plasminogen activator - Acute Pulmonary Embolism
Phase 2UnknownAngde Biotech Pharmaceutical Co., Ltd.1742019-10-012019-10-11
A PhaseⅡ of Injection for Recombinant Human Tissue Plasminogen Kinase Derivative in Treatment of Acute Ischemic Stroke.
r-PA, Alteplase for Injection - Acute Ischemic Stroke
Phase 2UnknownAngde Biotech Pharmaceutical Co., Ltd.1802019-07-202019-07-22
A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor
Chemotherapy-induced Thrombocytopenia
UnknownAngde Biotech Pharmaceutical Co., Ltd.20002017-02-282017-02-10

Conditions studied

Ischemic Stroke (2)

Interventions

Tissue Plasminogen Activator (3)  ·  Injections (1)  ·  reteplase (1)

Countries

China (4)

Top investigators

Yongjun Wang (1)

Results publications

PMID 38152962, PMID 38286482, PMID 38884332, PMID 40180551, PMID 42089199